By Maria Armental 

Thermo Fisher Scientific Inc. will buy Affymetrix Inc. in a roughly $1.3 billion cash deal that would boost its biogenetic analysis portfolio, the company said Friday.

Under the terms of the deal, which requires approval by Affymetrix shareholders, Thermo Fisher is to pay $14 a share in cash. Affymetrix's shares closed Friday at $9.21.

Thermo Fisher said the deal, which it expects to close by the end of the second quarter, would add 10 cents a share to adjusted profit in the first full year of ownership and result in about $70 million in savings by year three.

Santa Clara, Calif.-based Affymetrix, which carried an accumulated loss of about $500 million as of Sept. 30, has about $350 million in annual revenue, while Waltham, Mass.-based Thermo Fisher has about $17 billion in annual revenue, according to regulatory filings.

Write to Maria Armental at maria.armental@wsj.com

 

(END) Dow Jones Newswires

January 08, 2016 18:43 ET (23:43 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Thermo Fisher Scientific Charts.
Thermo Fisher Scientific (NYSE:TMO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Thermo Fisher Scientific Charts.